CHANNEL THERAPEUTICS CORP(NYSEARCA:CHRO) stock Fundamental Analysis

Fundamental Rating

Overall CHRO gets a fundamental rating of 1 out of 10. We evaluated CHRO against 572 industry peers in the Biotechnology industry. While CHRO seems to be doing ok healthwise, there are quite some concerns on its profitability. CHRO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CHRO has reported negative net income.

In the past year CHRO has reported a negative cash flow from operations.

1.2 Ratios

With a Return On Assets value of -222.66%, CHRO is not doing good in the industry: 91.50% of the companies in the same industry are doing better.

CHRO has a Return On Equity of -794.30%. This is amonst the worse of the industry: CHRO underperforms 82.83% of its industry peers.

		Industry Rank	Sector Rank
ROA	-222.66%
ROE	-794.3%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CHRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CHRO has about the same amount of shares outstanding.

The debt/assets ratio for CHRO is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -10.50, we must say that CHRO is in the distress zone and has some risk of bankruptcy.

CHRO has a Altman-Z score of -10.50. This is in the lower half of the industry: CHRO underperforms 75.58% of its industry peers.

There is no outstanding debt for CHRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-10.5

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CHRO has a Current Ratio of 1.39. This is a normal value and indicates that CHRO is financially healthy and should not expect problems in meeting its short term obligations.

CHRO's Current ratio of 1.39 is on the low side compared to the rest of the industry. CHRO is outperformed by 83.01% of its industry peers.

CHRO has a Quick Ratio of 1.39. This is a normal value and indicates that CHRO is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.39, CHRO is doing worse than 82.30% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.39
Quick Ratio	1.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CHRO have decreased strongly by -203.01% in the last year.

EPS 1Y (TTM)-203.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-221.31%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CHRO will show a small growth in Earnings Per Share. The EPS will grow by 5.17% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-3.62%

EPS Next 2Y5.98%

EPS Next 3Y5.17%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHRO. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y5.98%

EPS Next 3Y5.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CHRO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CHANNEL THERAPEUTICS CORP

NYSEARCA:CHRO (1/17/2025, 8:04:02 PM)

After market: 2.06 +0.16 (+8.42%)

1.9

+0.94 (+97.92%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner Change0%

Ins OwnersN/A

Ins Owner Change0%

Market Cap11.46M

Analysts82.86

Price Target8.67 (356.32%)

Short Float %0.09%

Short Ratio0.01

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	10.14
P/tB	10.14
EV/EBITDA	N/A

EPS(TTM)-1.67

EYN/A

EPS(NY)-1.12

Fwd EYN/A

FCF(TTM)-0.46

FCFYN/A

OCF(TTM)-0.46

OCFYN/A

SpS0

BVpS0.19

TBVpS0.19

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-222.66%
ROE	-794.3%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.39
Quick Ratio	1.39
Altman-Z	-10.5

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-203.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-221.31%

EPS Next Y-3.62%

EPS Next 2Y5.98%

EPS Next 3Y5.17%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-167.63%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y37.4%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y37.4%

OCF growth 3YN/A

OCF growth 5YN/A

CHANNEL THERAPEUTICS CORP (CHRO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens